Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

OTHER × Lung Cancer Metastatic × Ipilimumab × Clear all

Phase

Status

Active not recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Melanoma 122 Carcinoma, Non-Small-Cell Lung 33 Carcinoma, Renal Cell 29 Neoplasm Metastasis 28 Prostatic Neoplasms 19 Brain Neoplasms 19 Pancreatic Neoplasms 16 Lung Neoplasms 16 Neoplasms 15 Uveal Melanoma 14 Breast Neoplasms 13 Sarcoma 12 Carcinoma, Hepatocellular 12 Skin Neoplasms 10 Kidney Neoplasms 10 Urinary Bladder Neoplasms 8 Squamous Cell Carcinoma of Head and Neck 8 Triple Negative Breast Neoplasms 7 Small Cell Lung Carcinoma 7 Ovarian Neoplasms 7 Glioblastoma 7 Colorectal Neoplasms 7 Colonic Neoplasms 7 Recurrence 6 Multiple Myeloma 6 Diabetes Mellitus, Insulin-Dependent, 12 6 Clear-cell metastatic renal cell carcinoma 6 Carcinoma, Transitional Cell 6 Uterine Cervical Neoplasms 5 Rectal Neoplasms 5

Interventions

regramostim 1 osimertinib 1 evolocumab 1 Surgical Instruments 1 Radiotherapy 1 Radiation 1 Nivolumab 1 Needles 1 MLN 8237 1 Ipilimumab 1 Granulocyte-Macrophage Colony-Stimulating Factor 1 Cisplatin 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT05144529 2025-04-17

TOP2101

Duke University

Phase 2 Active not recruiting

Lung Cancer Metastatic

Data powered by HemOnc (CC BY 4.0) Colophon ⚡